Search
Roivant Sciences Ltd
ROIVAdd to Watchlist
32.955USD
+0.745+2.31%
Market hours （ET）Quotes delayed by 15 min
23.39BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.31%
5 Days
+8.37%
1 Month
+10.00%
6 Months
+46.79%
Year to Date
+51.87%
1 Year
+186.57%
Key Figures
32.250Open
33.090High
925.04KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.13%Turnover Ratio
32.210Prev. Close
32.000Low
20.43MTurnover
LossP/E Static
5.48P/B
0.00%Div Yield TTM
-7.14%ROA
32.79252wk High
1.06Volume Ratio
-171.98MNet Profit
709.69MShares
-0.4320EPS TTM
1.14Beta
-6.51%ROE
10.59452wk Low
3.38%Amplitude
87.30%Gross Margin
23.39BMarket Cap
3.79Reward/Risk
1.98%Risk Rate
TradingKey Stock Score of Roivant Sciences Ltd
Currency: USD Updated: 2026-06-23Key Insights
Roivant Sciences Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 30 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 38.59.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Roivant Sciences Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Roivant Sciences Ltd Highlights
StrengthsRisks
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Growing
The company is in a growing phase, with the latest annual income totaling USD 8.26M.
Undervalued
The company’s latest PE is -74.56, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 565.52M shares, decreasing 3.91% quarter-over-quarter.
Held by David Einhorn
Star Investor David Einhorn holds 2.02M shares of this stock.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
38.591
Target Price
+23.49%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Roivant Sciences Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Roivant Sciences Ltd Info
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Ticker SymbolROIV
CompanyRoivant Sciences Ltd
CEOVenker (Eric)
Websitehttp://roivant.com/
Related Instruments
+1.06%
+1.08%
+1.50%
+0.18%
+1.08%
+0.29%
+1.37%
-0.20%
+0.56%
+0.16%
+1.35%
+0.59%
-0.56%
+0.76%
+1.11%
0.00%
+0.99%
+1.86%
+0.97%
+0.25%Popular Instruments
70.159
-2.786 (-3.82%)
294.805
+0.505 (+0.17%)
199.365
-0.675 (-0.34%)
4023.650
-87.100 (-2.12%)
651.256
-19.494 (-2.91%)
1960.650
-2.950 (-0.15%)
1052.660
+0.890 (+0.08%)
350.476
+4.346 (+1.26%)
61216.010
-1224.690 (-1.96%)
381.285
-0.325 (-0.09%)
FAQs
What is the current price of Roivant Sciences Ltd (ROIV)?
The current price of Roivant Sciences Ltd (ROIV) is 32.21.
What is the symbol of Roivant Sciences Ltd?
The ticker symbol of Roivant Sciences Ltd is ROIV.
What is the 52-week high of Roivant Sciences Ltd?
The 52-week high of Roivant Sciences Ltd is 32.79.
What is the 52-week low of Roivant Sciences Ltd?
The 52-week low of Roivant Sciences Ltd is 10.59.
What is the market capitalization of Roivant Sciences Ltd?
The market capitalization of Roivant Sciences Ltd is 23.17B.
Is Roivant Sciences Ltd (ROIV) currently rated as Buy, Hold, or Sell?
According to analysts, Roivant Sciences Ltd (ROIV) has an overall rating of Buy, with a price target of 38.59.
What is the Earnings Per Share (EPS TTM) of Roivant Sciences Ltd (ROIV)?
The Earnings Per Share (EPS TTM) of Roivant Sciences Ltd (ROIV) is -0.43.
